Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gene and drug matrix for personalized cancer therapy.

Literature DB >> 20671766

Gene and drug matrix for personalized cancer therapy.

Tim Harris.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2010 PMID： 20671766 DOI： 10.1038/nrd3181-c1

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

10 in total

1. Third-generation sequencing fireworks at Marco Island.

Authors: David J Munroe; Timothy J R Harris
Journal: Nat Biotechnol Date: 2010-05 Impact factor: 54.908

Review 2. Targeting cancer with small molecule kinase inhibitors.

Authors: Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal: Nat Rev Cancer Date: 2009-01 Impact factor: 60.716

3. Cancer research. Melanoma drug vindicates targeted approach.

Authors: Ken Garber
Journal: Science Date: 2009-12-18 Impact factor: 47.728

Review 4. Personalized medicine in oncology: the future is now.

Authors: Richard L Schilsky
Journal: Nat Rev Drug Discov Date: 2010-05 Impact factor: 84.694

Review 5. The molecular pathology of cancer.

Authors: Timothy J R Harris; Frank McCormick
Journal: Nat Rev Clin Oncol Date: 2010-03-30 Impact factor: 66.675

6. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Authors: Jiannong Li; Uwe Rix; Bin Fang; Yun Bai; Arthur Edwards; Jacques Colinge; Keiryn L Bennett; Jingchun Gao; Lanxi Song; Steven Eschrich; Giulio Superti-Furga; John Koomen; Eric B Haura
Journal: Nat Chem Biol Date: 2010-02-28 Impact factor: 15.040

7. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors: Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal: Science Date: 2007-04-26 Impact factor: 47.728

Review 8. Inhibition of ALK signaling for cancer therapy.

Authors: Yael P Mossé; Andrew Wood; John M Maris
Journal: Clin Cancer Res Date: 2009-09-08 Impact factor: 12.531

9. Pazopanib.

Authors: Ronald M Bukowski; Uma Yasothan; Peter Kirkpatrick
Journal: Nat Rev Drug Discov Date: 2010-01 Impact factor: 84.694

10. Profiling critical cancer gene mutations in clinical tumor samples.

Authors: Laura E MacConaill; Catarina D Campbell; Sarah M Kehoe; Adam J Bass; Charles Hatton; Lili Niu; Matt Davis; Keluo Yao; Megan Hanna; Chandrani Mondal; Lauren Luongo; Caroline M Emery; Alissa C Baker; Juliet Philips; Deborah J Goff; Michelangelo Fiorentino; Mark A Rubin; Kornelia Polyak; Jennifer Chan; Yuexiang Wang; Jonathan A Fletcher; Sandro Santagata; Gianni Corso; Franco Roviello; Ramesh Shivdasani; Mark W Kieran; Keith L Ligon; Charles D Stiles; William C Hahn; Matthew L Meyerson; Levi A Garraway
Journal: PLoS One Date: 2009-11-18 Impact factor: 3.240

10 in total

5 in total

Review 1. The challenges associated with molecular targeted therapies for glioblastoma.

Authors: Toni Rose Jue; Kerrie L McDonald
Journal: J Neurooncol Date: 2016-02-22 Impact factor: 4.130

2. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Authors: Jesper B Andersen; Bart Spee; Boris R Blechacz; Itzhak Avital; Mina Komuta; Andrew Barbour; Elizabeth A Conner; Matthew C Gillen; Tania Roskams; Lewis R Roberts; Valentina M Factor; Snorri S Thorgeirsson
Journal: Gastroenterology Date: 2011-12-13 Impact factor: 22.682